NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, Price Target & More

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Syndax Pharmaceuticals Inc (NASDAQ:SNDX) announced its quarterly earnings results on Monday, March, 5th. The company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.76) by $0.04. The business earned $1.19 million during the quarter, compared to analysts' expectations of $0.75 million. Syndax Pharmaceuticals had a negative net margin of 2,884.34% and a negative return on equity of 63.51%. The business's revenue was up 290.2% on a year-over-year basis. View Syndax Pharmaceuticals' Earnings History.

Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Syndax Pharmaceuticals.

7 equities research analysts have issued 12 month price objectives for Syndax Pharmaceuticals' stock. Their predictions range from $20.00 to $40.00. On average, they expect Syndax Pharmaceuticals' share price to reach $26.1667 in the next year. View Analyst Ratings for Syndax Pharmaceuticals.

Syndax Pharmaceuticals saw a decrease in short interest in the month of March. As of March 29th, there was short interest totalling 967,476 shares, a decrease of 42.3% from the March 15th total of 1,676,430 shares. Based on an average daily volume of 352,354 shares, the days-to-cover ratio is presently 2.7 days. Approximately 5.6% of the company's stock are sold short.

Some companies that are related to Syndax Pharmaceuticals include CytomX Therapeutics (CTMX), MacroGenics (MGNX), Biohaven Pharmaceutical (BHVN), Flexion Therapeutics (FLXN), Uniqure (QURE), Epizyme (EPZM), Amphastar Pharmaceuticals (AMPH), Inflarx (IFRX), Assembly Biosciences (ASMB), Zai Lab (ZLAB), Alder BioPharmaceuticals (ALDR), Access Pharmaceuticals (ABEO), Lexicon Pharmaceuticals (LXRX), Eagle Pharmaceuticals (EGRX) and Mirati Therapeutics (MRTX).

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

Media coverage about SNDX stock has been trending somewhat negative recently, according to Accern. The research group scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Syndax Pharmaceuticals earned a news sentiment score of -0.10 on Accern's scale. They also gave news stories about the company an impact score of 47.60 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.

Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of SNDX stock can currently be purchased for approximately $10.63.

Syndax Pharmaceuticals has a market capitalization of $253.15 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe.

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected]